U.S. Updates Hepatitis B Vaccine Guidelines to Target Newborns at Risk of Infection
A new U.S. policy limits hepatitis B vaccine recommendations at birth to babies at risk of neonatal infection. Separately, Intellia Therapeutics reported positive trial results for its CRISPR treatment, and federal regulators announced new pathways for device coverage and psychedelics reviews. The Trump administration warned against federal funding for fentanyl test strips.
upi.comU.S. policy recommends offering the hepatitis B vaccine at birth only to babies perceived to be at risk of neonatal infection. The announcement, published three hours ago, marks a shift in vaccination guidelines.
@statnews reported that studies project dire consequences from this change. Intellia Therapeutics announced on Monday that a single dose of its CRISPR-based gene editing treatment reduced swelling attacks in patients with a rare disease in a pivotal trial. The company detailed dramatic reductions in attacks following the treatment.
This update was published 13 hours ago. Federal regulators announced on Thursday a new Medicare coverage pathway for devices deemed breakthroughs by the Food and Drug Administration.
@statnews reported the announcement four days ago. The FDA will speed up review of three psychedelics as mental health treatments. This decision aims to accelerate evaluations for potential therapeutic uses.
The Trump administration issued an open letter on April warning against using federal dollars on fentanyl test strips. The administration is opposing harm reduction services for people who use illicit drugs.
Sen. ) asked health secretary Robert F. Kennedy Jr. last week whether he would release a contract by Friday. Democrats state that Robert F. Kennedy Jr. has a pattern of failing to answer their questions.
Key Facts
Story Timeline
6 events- 3 hours ago
New U.S. recommendation on hepatitis B vaccine published.
1 source@statnews - 4 hours ago
Democrats' statement on RFK Jr. published.
1 source@statnews - 5 hours ago
Trump administration warning on fentanyl test strips published.
1 source@statnews - 13 hours ago
Intellia Therapeutics trial announcement published.
1 source@statnews - 3 days ago
FDA psychedelics review announcement published.
1 source@statnews - 4 days ago
CMS and FDA announcement on breakthrough devices published.
1 source@statnews
Potential Impact
- 01
Accelerated development and approval of CRISPR treatments for rare diseases.
- 02
Restrictions on harm reduction tools amid opioid crisis.
- 03
Potential increase in hepatitis B infections among newborns due to limited vaccine access.
- 04
Increased scrutiny on health secretary's transparency in contracts.
Transparency Panel
Related Stories
deccanchronicle.comHantavirus Cases Reported on MV Hondius Cruise Ship, Three Fatalities Amid Low Transmission Risk
A hantavirus outbreak on the MV Hondius cruise ship has killed three passengers and sickened seven others, prompting an international response coordinated by the World Health Organization. The ship, carrying 147 people from 23 nationalities, is set to sail to Spain's Canary Islan…
techjuice.pkImperial College London Study Analyzes Changes in Wildfire Weather Patterns in Northern Ireland
A new report from Imperial College London highlights growing wildfire threats in Northern Ireland due to more favorable conditions, especially in spring. Researchers note increased drought and fire-prone weather, exacerbated by climate change. The findings point to longer fire se…
FDA Commissioner Defends Drug Rejection Decisions
The FDA commissioner defended recent drug rejections in a CNBC interview, citing adherence to scientific reviews amid reports of agency turmoil. Criticism includes a high-profile denial of a melanoma treatment from Replimune and pressure from President Trump over vape approvals.…